
The Final Frontier of Drug Delivery: Navigating the Blood-Brain Barrier
The next generation of CNS therapies will depend on crossing the blood-brain barrier safely, selectively, and at therapeutic scale.


Recuro Health, recognized by Newsweek and Statista as one of the “World’s Best Digital Health Companies 2024,” stands out for its comprehensive virtual care solutions—including primary care, urgent care, behavioral health, genomics, and at-home diagnostics—underscoring its role as a telehealth leader
The inaugural Newsweek ranking assessed 400 digital health companies across 35 countries in sectors such as diagnostics, health records, medical management, and telehealth. Recuro’s inclusion reflects strong performance in technology, impact, and patient accessibility
Phil Fasano, CEO and Chairman of Recuro, shared:
“We are honored to be recognized among the world’s top digital health companies by Newsweek… a testament to our relentless dedication to delivering innovative and accessible healthcare solutions that improve patient outcomes
Dr. Kate Sowerwine, Chief Medical Officer, added that Recuro’s “Complete Care all‑in‑one solution”—integrating genomic testing, at‑home labs, and health risk assessments—improves outcomes and reduces costs for employers and patients alike
Shortly after, Becker’s Hospital Review named Recuro among the Top 10 companies in at-home care, citing its integrated virtual primary, behavioral, and urgent care offerings
Recuro’s virtual-first care platform delivers holistic, personalized healthcare—24/7 access to primary, urgent, and behavioral care, supplemented with lab and genomic testing—supporting proactive and coordinated patient care
This recognition underscores Recuro’s commitment to reducing care barriers, enhancing patient outcomes, and driving cost efficiency through advanced virtual care services. It also reinforces its strategic vision to redefine how healthcare is accessed and delivered

The next generation of CNS therapies will depend on crossing the blood-brain barrier safely, selectively, and at therapeutic scale.

Even the strongest science does not guarantee an investable asset. Here, we discuss how to align early-stage discovery programs for small molecules with investor expectations in a complex biotech funding environment.
Join us in building the future of medicine through innovative technology and biology convergence